| 1 |
35532254 | Bringing the Spotlight to tau and TDP-43 in Frontotemporal Dementia: A Review of Promising Chemical Compounds. | 2022 May 8 |
1 |
| 2 |
32037892 | An evaluation of hydromethylthionine as a treatment option for Alzheimer's disease. | 2020 Apr |
1 |
| 3 |
29944336 | Structural Basis of Small Molecule Targetability of Monomeric Tau Protein. | 2018 Dec 19 |
4 |
| 4 |
28287136 | A Dual Pathogenic Mechanism Links Tau Acetylation to Sporadic Tauopathy. | 2017 Mar 13 |
2 |
| 5 |
25958115 | Preventive methylene blue treatment preserves cognition in mice expressing full-length pro-aggregant human Tau. | 2015 May 10 |
3 |
| 6 |
24361915 | Tau-aggregation inhibitor therapy for Alzheimer's disease. | 2014 Apr 15 |
2 |
| 7 |
24556215 | Methylene blue upregulates Nrf2/ARE genes and prevents tau-related neurotoxicity. | 2014 Jul 15 |
2 |
| 8 |
23443659 | Aminothienopyridazines and methylene blue affect Tau fibrillization via cysteine oxidation. | 2013 Apr 19 |
3 |
| 9 |
21222635 | Alzheimer's disease: from pathogenesis to disease-modifying approaches. | 2011 Mar |
1 |
| 10 |
20298170 | Treatment of Alzheimer's disease: symptomatic and disease-modifying approaches. | 2010 Feb |
1 |
| 11 |
20154508 | Beyond the neurotransmitter-focused approach in treating Alzheimer's disease: drugs targeting beta-amyloid and tau protein. | 2009 Dec |
1 |
| 12 |
18619417 | Different inhibitory response of cyanidin and methylene blue for filament formation of tau microtubule-binding domain. | 2008 Sep 12 |
2 |
| 13 |
8855335 | Selective inhibition of Alzheimer disease-like tau aggregation by phenothiazines. | 1996 Oct 1 |
2 |